In the high-stakes world of biopharmaceutical manufacturing, the transition from clinical-stage promise to commercial-scale reality is often where innovation goes to die. As global demand for biologics and advanced therapies surges, Contract Development and Manufacturing Organizations (CDMOs) are finding that traditional, rigid manufacturing models are no longer sufficient. Leading this charge at FUJIFILM Biotechnologies is Chief Operating Officer Maja Herold Pedersen, a veteran executive whose career trajectory—from quality assurance to operational leadership—is now defining a new era of "intelligent" biomanufacturing.
The Architecture of a Global Expansion
FUJIFILM Biotechnologies is currently orchestrating one of the most ambitious infrastructure build-outs in the history of the life sciences industry. With roughly $7 billion in capital projects currently underway across North America and Europe, the company is positioning itself to be the primary backbone for the next generation of therapeutic breakthroughs.
The crown jewel of this expansion is the $3.2 billion manufacturing campus in Holly Springs, North Carolina. Following the successful launch of its first phase in September 2025, the facility is already serving as a model for modern, large-scale cell culture manufacturing. With a second phase already on the horizon for 2028, the Holly Springs site represents a commitment to high-volume production capable of meeting global drug supply requirements.
The expansion is not limited to the United States. In Denmark, the company is significantly scaling its Hillerød campus, integrating eight new 20,000-liter bioreactors alongside two advanced downstream processing streams. This expansion is designed to provide the massive capacity required for blockbuster biologics. Meanwhile, in the United Kingdom, the company unveiled its Teesside facility in early 2026—the largest single-use CDMO site in the country—designed to provide maximum agility for agile, smaller-batch clinical production.
Simultaneously, the sister subsidiary, FUJIFILM Cellular Dynamics, is pushing the boundaries of regenerative medicine. In May 2026, the company opened a new induced pluripotent stem cell (iPSC) manufacturing headquarters in Madison, Wisconsin. This $200 million investment is projected to quadruple the company’s capacity for stem cell production, a critical component in the future of personalized medicine.
The "kojoX" Philosophy: Standardizing the Extraordinary
At the heart of this sprawling, multi-continental network is a proprietary operational model known as kojoX. Fusing the Japanese word kojo (a compound meaning "improvement" and "factory") with an "X" to denote exponential scalability, the model is the company’s solution to the "tech-transfer trap."
By standardizing equipment, quality systems, and processes across all global sites, FUJIFILM Biotechnologies aims to make technology transfer almost seamless. A drug substance process validated in one facility can theoretically be ported to an equivalent line anywhere in the global network, significantly compressing the time-to-market for clients and simplifying the regulatory pathway.
Leadership in Transition: From Quality to Operations
The person overseeing this complex operational web is Maja Herold Pedersen. Her transition from Chief Quality Officer to Chief Technology Officer, and finally to COO in September 2025, is a testament to the changing requirements of the biopharmaceutical C-suite.
"Lars Petersen, our CEO, knew me from before and knows how I lead," Pedersen explained in a recent interview. "I’ve never been a quality-function-only leader. I’ve always looked at the whole picture of how we get medicine to patients. It doesn’t matter whether I’m wearing a quality hat or some other hat, we need to make this work for patients in the end."
Her background in quality, often viewed as the "brakes" of a manufacturing organization, has provided her with a unique perspective on how to integrate high-velocity technology, like Artificial Intelligence, into a strictly regulated GMP (Good Manufacturing Practice) environment.
AI as a Catalyst: Moving Beyond the Pilot Phase
For many in the pharmaceutical sector, AI remains an experimental toy—a collection of "pilot projects" that rarely see the light of day on the production floor. Pedersen views this hesitancy as a failure of imagination.
"In this industry, we have a tendency to think we can’t really do it because we can’t validate it," Pedersen notes. "There’s some truth to that, but it shouldn’t hold us back. On the contrary, it should make us move faster. We can apply a human check before we let something go. Let’s make use of it up to the point where a human brain really needs to make the assessment."
To operationalize this, the company developed "GenkiBot," an internal, secure generative AI platform. Named for the Japanese concept of enthusiasm and positive energy, GenkiBot serves as a sandbox for employees to utilize LLM capabilities without the risks associated with public-facing AI tools.
The application of GenkiBot has already yielded tangible results in deviation management. By coaching subject matter experts (SMEs) on how to document deviations and helping them analyze data for root causes, the system is reducing the time-sink of manual administrative tasks. Currently, about 50% of users in relevant departments are utilizing the tool, a number Pedersen is eager to drive toward 100%.
The Strategy of "Setting Agents Free"
Perhaps the most provocative element of Pedersen’s strategy is her approach to AI agents. Rather than creating a rigid, top-down hierarchy of approved AI applications, she advocates for a decentralized model.
"I’m a big believer that scaling only follows the actual speed if we set it free," Pedersen says. Her vision involves equipping staff with the ability to "code" their own agents—similar to how employees once used Excel macros to solve localized problems. "The bigger the funnel we have of agents being coded, the better the quality of the selected variety of agents we’ll have at the end, which we can then take into a more controlled environment."
This strategy aims to solve the "tech transfer" bottleneck. By training AI agents to aggregate data, organize documentation, and prepare the necessary sequences for new product introductions, the company hopes to strip away the "tedious" work that often delays the start of production.
Culture as the Operating System: The 9 People Fundamentals
No amount of technology can compensate for a rigid or fearful culture. To support this digital transformation, Pedersen and her leadership team have implemented the "9 People Fundamentals," a framework designed to push decision-making to the edges of the organization.
The philosophy treats the company as a living organism. "We have our brain, and then we have numerous cells out in the body, and they actually work very well individually," Pedersen explains. "But the immediacy of what each individual can do when they’re set free—that’s what we need in the future."
This empowerment, however, comes with a caveat. The company is currently running a "Leaders for Life" cohort, an intensive program designed to help leaders confront their own biases and reactions. "Being empowered doesn’t come for free," Pedersen admits. "It holds you very accountable for what you’re doing and the moves you make."
Implications for the Future of Biopharma
The implications of Pedersen’s approach are significant. By blending massive physical infrastructure with a decentralized, AI-augmented human workforce, FUJIFILM Biotechnologies is attempting to solve the industry’s "scalability dilemma."
If successful, the model proves that even the most heavily regulated industries can move with the agility of tech companies. The shift toward AI-assisted, decentralized manufacturing suggests a future where drug production is not only faster but more resilient to supply chain disruptions.
As Pedersen continues to steer the company’s operations, her focus remains clear: the technology, the expansion, and the culture are all merely tools in the service of the end goal. "We need to make this work for patients in the end," she concludes. For a company investing billions into the future of medicine, that patient-centric mandate is the only metric that truly matters.
About the Author
